Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13919889 | 0.82 | GSK3B (0.69) | GSK3BMEN1KMT2AMAPTPOLB | |
| SCHEMBL143904 | 0.82 | GSK3B (1.00) | GSK3BMEN1KMT2AMAPTPOLB | |
| SCHEMBL30844757 | 0.80 | GSK3B (0.67) | GSK3BMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL12294979 | 0.80 | GSK3B (0.67) | GSK3BMEN1KMT2AMAPTKDM4E | |
| SCHEMBL3900686 | 0.80 | GSK3B (0.67) | GSK3BMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL23330896 | 0.79 | GSK3B (0.65) | GSK3BMEN1KMT2AMAPTPOLB | |
| SCHEMBL8923637 | 0.79 | GSK3B (0.65) | GSK3BMEN1KMT2AMAPTPOLB | |
| SCHEMBL15483703 | 0.77 | GSK3B (0.62) | GSK3BMEN1KMT2AMAPTPOLB | |
| SCHEMBL29745986 | 0.76 | GSK3B (0.61) | GSK3BMEN1KMT2AMAPTPOLB | |
| SCHEMBL23330785 | 0.76 | GSK3B (0.61) | GSK3BMEN1KMT2AMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6747057-B2 | SUCH 1-(2-BROMO-4,5-DICHLORO-THIOPHEN-3-YL)-2-CHLORO-ETHANONE FOR TREATMENT OF ALZHEIMER'S DISEASE OR DIABETES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2004-06-08 | — | — | US | disclosed |
| US-20030199508-A1 | Compounds and their therapeutic use | UNIVERSIDAD AUTONOMA DE MADRID (UAM) (ES) | 2003-10-23 | — | — | US | disclosed |
| WO-2003055479-A1 | COMPOUNDS AND THEIR THERAPEUTIC USE RELATED TO THE PHOSPHORYLATING ACTIVITY OF THE ENZYME GSK-3 | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2003-07-10 | — | — | WO | disclosed |
| US-4105663-A | HYPOTENSIVE, BLOCKING AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-08-08 | — | — | US | disclosed |
| US-4093628-A | HYPOTENSIVE AGENTS, BLOCKING AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199508-A1 | Compounds and their therapeutic use | CNKSR1, CBR1, CBR3 | GSK3B 4/4885MEN1 4253/4885KMT2A 2417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.